Research Analysts Offer Predictions for DBVT FY2026 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of DBV Technologies in a report released on Thursday, October 29th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.90) for the year, down from their prior forecast of ($1.75). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for DBV Technologies’ Q4 2026 earnings at ($0.75) EPS, FY2027 earnings at ($1.25) EPS, FY2029 earnings at $4.60 EPS and FY2030 earnings at $8.00 EPS.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41). The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.56 million. DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 120.95%.

Several other equities analysts have also recently weighed in on DBVT. Guggenheim lowered their price objective on shares of DBV Technologies from $51.00 to $46.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Citizens Jmp cut their price objective on shares of DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Thursday, October 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research report on Thursday, October 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DBV Technologies in a research note on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

DBV Technologies Stock Performance

DBV Technologies stock opened at $10.11 on Monday. The business has a 50-day simple moving average of $11.34 and a two-hundred day simple moving average of $16.85. DBV Technologies has a 52-week low of $8.63 and a 52-week high of $26.18.

Institutional Trading of DBV Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its stake in DBV Technologies by 170.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company’s stock worth $249,000 after buying an additional 13,600 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in DBV Technologies during the third quarter valued at about $144,000. Perceptive Advisors LLC bought a new stake in DBV Technologies during the first quarter valued at about $20,146,000. Vivo Capital LLC lifted its position in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of DBV Technologies in the first quarter valued at about $21,159,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.